Loading…
Are the metabolic effects of rosiglitazone influenced by baseline glycaemic control?
SUMMARY Objective: To compare the metabolic effects of rosiglitazone, an antidiabetic agent of the thiazolidinedione class, in patients with type 2 diabetes with fair to moderate glycaemic control (glycosylated haemoglobin (HbA1c) 9%). Research design and methods: Data were pooled from two 26-week,...
Saved in:
| Published in: | Current medical research and opinion 2003, Vol.19 (3), p.192-199 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c463t-3d55c4c300ce68480c492525c2c7e160c7ef6a5dfdc43ebb0017080696d3843 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c463t-3d55c4c300ce68480c492525c2c7e160c7ef6a5dfdc43ebb0017080696d3843 |
| container_end_page | 199 |
| container_issue | 3 |
| container_start_page | 192 |
| container_title | Current medical research and opinion |
| container_volume | 19 |
| creator | Goldstein, Barry J. Cobitz, Alexander R. Hand, Linda M. Chen, Hongzi |
| description | SUMMARY
Objective: To compare the metabolic effects of rosiglitazone, an antidiabetic agent of the thiazolidinedione class, in patients with type 2 diabetes with fair to moderate glycaemic control (glycosylated haemoglobin (HbA1c) 9%).
Research design and methods: Data were pooled from two 26-week, randomised, placebo-controlled, double-blind studies of rosiglitazone (4 and 8 mg/day).
Results: After 26 weeks of treatment, HbA1c was significantly reduced (p 9%. After 26 weeks of treatment, reductions in fasting plasma glucose (FPG) were significant (p |
| doi_str_mv | 10.1185/030079903125001695 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_infor</sourceid><recordid>TN_cdi_proquest_journals_207967076</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>348980441</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-3d55c4c300ce68480c492525c2c7e160c7ef6a5dfdc43ebb0017080696d3843</originalsourceid><addsrcrecordid>eNp9kEFr3DAQhUVpaTZp_0APxRSam1vJsiQbUkoITVoI5JDcjTweZR1kK5FkyubXZ8JuWdpCLjMwfG947zH2QfAvQjTqK5ecm7blUlSKc6Fb9YqtRG1kWTfGvGarZ6AkQh2ww5TuiKmatn3LDmhzaaRcsZvTiEVeYzFhtn3wIxToHEJORXBFDGm89WO2j2HGYpydX3AGHIp-U_Q2oR_pfOs3YHEiJYQ5x-C_v2NvnPUJ3-_2Ebs-_3Fz9rO8vLr4dXZ6WUKtZS7loBTUQCYBdVM3HOq2UpWCCgwKzWk6bdXgBqgl9j35N7zhutWDbGp5xI63X-9jeFgw5W4aE6D3dsawpI7yGc4rQeCnf8C7sMSZnHUVFagNN5qgagsBhU4RXXcfx8nGTSd491x393_dJPq4-7z0Ew57ya5fAj7vAJvAehftDGPacxS64aol7tuWo45DnOzvEP3QZbvxIf4RyReNnPylX6P1eQ024j7rC_Inh5asIw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>207967076</pqid></control><display><type>article</type><title>Are the metabolic effects of rosiglitazone influenced by baseline glycaemic control?</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Goldstein, Barry J. ; Cobitz, Alexander R. ; Hand, Linda M. ; Chen, Hongzi</creator><creatorcontrib>Goldstein, Barry J. ; Cobitz, Alexander R. ; Hand, Linda M. ; Chen, Hongzi</creatorcontrib><description><![CDATA[SUMMARY
Objective: To compare the metabolic effects of rosiglitazone, an antidiabetic agent of the thiazolidinedione class, in patients with type 2 diabetes with fair to moderate glycaemic control (glycosylated haemoglobin (HbA1c) < 9%) and poor glycaemic control (HbA1c > 9%).
Research design and methods: Data were pooled from two 26-week, randomised, placebo-controlled, double-blind studies of rosiglitazone (4 and 8 mg/day).
Results: After 26 weeks of treatment, HbA1c was significantly reduced (p < 0.05) compared with baseline and placebo in patients taking rosiglitazone 8mg/day for both HbA1c stratifications, with greater reductions in patients with baseline HbA1c >9%. After 26 weeks of treatment, reductions in fasting plasma glucose (FPG) were significant (p < 0.05) compared with baseline and placebo in both rosiglitazone treatment groups for both HbA1c stratifications, with greater reductions in the group with poor glycaemic control. Rosiglitazone significantly improved insulin sensitivity (p < 0.05) compared with baseline in patients with baseline HbA1c <9%. Rosiglitazone significantly improved beta-cell function (p < 0.05) compared with baseline with more improvement in the group with baseline HbA1c >9%. These improvements were statistically significant compared with placebo, regardless of HbA1c stratification.
Conclusion: Rosiglitazone significantly improved HbA1c and FPG levels in patients with type 2 diabetes, with the greatest improvements observed in patients with baseline HbA1c levels >9%.]]></description><identifier>ISSN: 0300-7995</identifier><identifier>EISSN: 1473-4877</identifier><identifier>DOI: 10.1185/030079903125001695</identifier><identifier>PMID: 12803733</identifier><identifier>CODEN: CMROCX</identifier><language>eng</language><publisher>Reading: Informa UK Ltd</publisher><subject>Beta-cell function ; Biological and medical sciences ; Blood Glucose - analysis ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - drug therapy ; Double-Blind Method ; Glycaemic control ; Glycated Hemoglobin A - analysis ; Humans ; Hypoglycemic Agents - pharmacology ; Hypoglycemic Agents - therapeutic use ; Insulin sensitivity ; Medical sciences ; Middle Aged ; Rosiglitazone ; Thiazoles - pharmacology ; Thiazoles - therapeutic use ; Thiazolidinediones ; Type</subject><ispartof>Current medical research and opinion, 2003, Vol.19 (3), p.192-199</ispartof><rights>2003 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2003</rights><rights>2003 INIST-CNRS</rights><rights>Copyright Librapharm 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-3d55c4c300ce68480c492525c2c7e160c7ef6a5dfdc43ebb0017080696d3843</citedby><cites>FETCH-LOGICAL-c463t-3d55c4c300ce68480c492525c2c7e160c7ef6a5dfdc43ebb0017080696d3843</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14808059$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12803733$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Goldstein, Barry J.</creatorcontrib><creatorcontrib>Cobitz, Alexander R.</creatorcontrib><creatorcontrib>Hand, Linda M.</creatorcontrib><creatorcontrib>Chen, Hongzi</creatorcontrib><title>Are the metabolic effects of rosiglitazone influenced by baseline glycaemic control?</title><title>Current medical research and opinion</title><addtitle>Curr Med Res Opin</addtitle><description><![CDATA[SUMMARY
Objective: To compare the metabolic effects of rosiglitazone, an antidiabetic agent of the thiazolidinedione class, in patients with type 2 diabetes with fair to moderate glycaemic control (glycosylated haemoglobin (HbA1c) < 9%) and poor glycaemic control (HbA1c > 9%).
Research design and methods: Data were pooled from two 26-week, randomised, placebo-controlled, double-blind studies of rosiglitazone (4 and 8 mg/day).
Results: After 26 weeks of treatment, HbA1c was significantly reduced (p < 0.05) compared with baseline and placebo in patients taking rosiglitazone 8mg/day for both HbA1c stratifications, with greater reductions in patients with baseline HbA1c >9%. After 26 weeks of treatment, reductions in fasting plasma glucose (FPG) were significant (p < 0.05) compared with baseline and placebo in both rosiglitazone treatment groups for both HbA1c stratifications, with greater reductions in the group with poor glycaemic control. Rosiglitazone significantly improved insulin sensitivity (p < 0.05) compared with baseline in patients with baseline HbA1c <9%. Rosiglitazone significantly improved beta-cell function (p < 0.05) compared with baseline with more improvement in the group with baseline HbA1c >9%. These improvements were statistically significant compared with placebo, regardless of HbA1c stratification.
Conclusion: Rosiglitazone significantly improved HbA1c and FPG levels in patients with type 2 diabetes, with the greatest improvements observed in patients with baseline HbA1c levels >9%.]]></description><subject>Beta-cell function</subject><subject>Biological and medical sciences</subject><subject>Blood Glucose - analysis</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Double-Blind Method</subject><subject>Glycaemic control</subject><subject>Glycated Hemoglobin A - analysis</subject><subject>Humans</subject><subject>Hypoglycemic Agents - pharmacology</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin sensitivity</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Rosiglitazone</subject><subject>Thiazoles - pharmacology</subject><subject>Thiazoles - therapeutic use</subject><subject>Thiazolidinediones</subject><subject>Type</subject><issn>0300-7995</issn><issn>1473-4877</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNp9kEFr3DAQhUVpaTZp_0APxRSam1vJsiQbUkoITVoI5JDcjTweZR1kK5FkyubXZ8JuWdpCLjMwfG947zH2QfAvQjTqK5ecm7blUlSKc6Fb9YqtRG1kWTfGvGarZ6AkQh2ww5TuiKmatn3LDmhzaaRcsZvTiEVeYzFhtn3wIxToHEJORXBFDGm89WO2j2HGYpydX3AGHIp-U_Q2oR_pfOs3YHEiJYQ5x-C_v2NvnPUJ3-_2Ebs-_3Fz9rO8vLr4dXZ6WUKtZS7loBTUQCYBdVM3HOq2UpWCCgwKzWk6bdXgBqgl9j35N7zhutWDbGp5xI63X-9jeFgw5W4aE6D3dsawpI7yGc4rQeCnf8C7sMSZnHUVFagNN5qgagsBhU4RXXcfx8nGTSd491x393_dJPq4-7z0Ew57ya5fAj7vAJvAehftDGPacxS64aol7tuWo45DnOzvEP3QZbvxIf4RyReNnPylX6P1eQ024j7rC_Inh5asIw</recordid><startdate>2003</startdate><enddate>2003</enddate><creator>Goldstein, Barry J.</creator><creator>Cobitz, Alexander R.</creator><creator>Hand, Linda M.</creator><creator>Chen, Hongzi</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><general>Librapharm</general><general>Informa Healthcare</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>2003</creationdate><title>Are the metabolic effects of rosiglitazone influenced by baseline glycaemic control?</title><author>Goldstein, Barry J. ; Cobitz, Alexander R. ; Hand, Linda M. ; Chen, Hongzi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-3d55c4c300ce68480c492525c2c7e160c7ef6a5dfdc43ebb0017080696d3843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Beta-cell function</topic><topic>Biological and medical sciences</topic><topic>Blood Glucose - analysis</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Double-Blind Method</topic><topic>Glycaemic control</topic><topic>Glycated Hemoglobin A - analysis</topic><topic>Humans</topic><topic>Hypoglycemic Agents - pharmacology</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin sensitivity</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Rosiglitazone</topic><topic>Thiazoles - pharmacology</topic><topic>Thiazoles - therapeutic use</topic><topic>Thiazolidinediones</topic><topic>Type</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goldstein, Barry J.</creatorcontrib><creatorcontrib>Cobitz, Alexander R.</creatorcontrib><creatorcontrib>Hand, Linda M.</creatorcontrib><creatorcontrib>Chen, Hongzi</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Complete (ProQuest Database)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Science Journals</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>Current medical research and opinion</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goldstein, Barry J.</au><au>Cobitz, Alexander R.</au><au>Hand, Linda M.</au><au>Chen, Hongzi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Are the metabolic effects of rosiglitazone influenced by baseline glycaemic control?</atitle><jtitle>Current medical research and opinion</jtitle><addtitle>Curr Med Res Opin</addtitle><date>2003</date><risdate>2003</risdate><volume>19</volume><issue>3</issue><spage>192</spage><epage>199</epage><pages>192-199</pages><issn>0300-7995</issn><eissn>1473-4877</eissn><coden>CMROCX</coden><abstract><![CDATA[SUMMARY
Objective: To compare the metabolic effects of rosiglitazone, an antidiabetic agent of the thiazolidinedione class, in patients with type 2 diabetes with fair to moderate glycaemic control (glycosylated haemoglobin (HbA1c) < 9%) and poor glycaemic control (HbA1c > 9%).
Research design and methods: Data were pooled from two 26-week, randomised, placebo-controlled, double-blind studies of rosiglitazone (4 and 8 mg/day).
Results: After 26 weeks of treatment, HbA1c was significantly reduced (p < 0.05) compared with baseline and placebo in patients taking rosiglitazone 8mg/day for both HbA1c stratifications, with greater reductions in patients with baseline HbA1c >9%. After 26 weeks of treatment, reductions in fasting plasma glucose (FPG) were significant (p < 0.05) compared with baseline and placebo in both rosiglitazone treatment groups for both HbA1c stratifications, with greater reductions in the group with poor glycaemic control. Rosiglitazone significantly improved insulin sensitivity (p < 0.05) compared with baseline in patients with baseline HbA1c <9%. Rosiglitazone significantly improved beta-cell function (p < 0.05) compared with baseline with more improvement in the group with baseline HbA1c >9%. These improvements were statistically significant compared with placebo, regardless of HbA1c stratification.
Conclusion: Rosiglitazone significantly improved HbA1c and FPG levels in patients with type 2 diabetes, with the greatest improvements observed in patients with baseline HbA1c levels >9%.]]></abstract><cop>Reading</cop><pub>Informa UK Ltd</pub><pmid>12803733</pmid><doi>10.1185/030079903125001695</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-7995 |
| ispartof | Current medical research and opinion, 2003, Vol.19 (3), p.192-199 |
| issn | 0300-7995 1473-4877 |
| language | eng |
| recordid | cdi_proquest_journals_207967076 |
| source | Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list) |
| subjects | Beta-cell function Biological and medical sciences Blood Glucose - analysis Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Double-Blind Method Glycaemic control Glycated Hemoglobin A - analysis Humans Hypoglycemic Agents - pharmacology Hypoglycemic Agents - therapeutic use Insulin sensitivity Medical sciences Middle Aged Rosiglitazone Thiazoles - pharmacology Thiazoles - therapeutic use Thiazolidinediones Type |
| title | Are the metabolic effects of rosiglitazone influenced by baseline glycaemic control? |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T11%3A41%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_infor&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Are%20the%20metabolic%20effects%20of%20rosiglitazone%20influenced%20by%20baseline%20glycaemic%20control?&rft.jtitle=Current%20medical%20research%20and%20opinion&rft.au=Goldstein,%20Barry%20J.&rft.date=2003&rft.volume=19&rft.issue=3&rft.spage=192&rft.epage=199&rft.pages=192-199&rft.issn=0300-7995&rft.eissn=1473-4877&rft.coden=CMROCX&rft_id=info:doi/10.1185/030079903125001695&rft_dat=%3Cproquest_infor%3E348980441%3C/proquest_infor%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c463t-3d55c4c300ce68480c492525c2c7e160c7ef6a5dfdc43ebb0017080696d3843%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=207967076&rft_id=info:pmid/12803733&rfr_iscdi=true |